Supplement Figure 3(B) Impact of nab-paclitaxel plus PD-1/PD-L1 inhibitor on chemorefractory relapsed small-cell lung cancer

This research was supported by National Natural Science Foundation of China (grant no. 82172865), Start-up fund of Shandong Cancer Hospital (grant no. 2020-B14), Clinical Research Special Fund of Wu Jieping Medical Foundation (grant nos. 320.6750.2021-02-51 and 320.6750.2021-17-13). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.